On July 16, 2024, it was learned from Peking University Cancer Hospital that the Phase I clinical trial of the innovative anti-tumor drug BTK inhibitor TM471-1 capsule developed by EMICRO Biomedicine Company has passed the ethical review of the hospital's ethics committee and obtained ethical review approval.

　　The leading unit for the Phase I clinical trial of the EMICRO Innovative Drug Project is Peking University Cancer Hospital, with the leading department being the Department of Lymphatic Oncology. The ethical review approval number is 2024YW132. The BTK inhibitor TM471-1 capsule will undergo phase I clinical trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with B-cell non Hodgkin lymphoma.

　　The Lymphoma Department of Peking University Cancer Hospital is the earliest specialized lymphoma department established in China, and is an authoritative institution specializing in the clinical diagnosis and treatment of lymphoma. The patients admitted to this hospital almost cover all subtypes of lymphoma classified by the World Health Organization. Professor Zhu Jun is a renowned expert in the field of hematological oncology treatment in China. He is the Secretary of the Party Committee, Director of the Department of Internal Medicine, and Director of the Lymphoma Department at Peking University Cancer Hospital. The research team he led chose to cooperate with EMICRO Company because they were optimistic about the drug development, cutting-edge, and forward-looking nature of the project.

　　It is reported that the Phase I clinical trial will also be conducted simultaneously at Henan Cancer Hospital, the First Affiliated Hospital of Zhengzhou University, and the First People's Hospital of Chenzhou City. The first subject was enrolled.